FDA最高警报拉响:血管植入物致命缺陷暴露2025年3月3日,美国FDA一纸公告将飞利浦(PHG.US)推上风口浪尖——其Tack血管内系统因可能导致血栓、截肢甚至死亡的设计缺陷,被列为最高级别的一级召回。这已是继呼吸机致癌泡沫、LED电池起火后,飞利浦三年内第三次因重大安全隐患遭到全球监管重锤。技术失控的代价:20例伤害背后的系统风险此次召回的三款Tack血管植入物,主要用于血管成形术后的修复,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.